National Cancer Centre, Singapore
nccs.com.sgLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
113
Active
34
Phase 3
7
Total enrollment
50,927
Pipeline matrix
Showing 15 of 15 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Nivolumab | — | — | — | — | — | 6 | |
| Ipilimumab | — | — | — | — | — | 2 | |
| Pembrolizumab IV infusion Q3W, with daily oral Olaparib. | — | — | — | — | — | 1 | |
| SIRT-Y90 with Atezolizumab + Bevacizumab | — | — | — | — | — | 1 | |
| SIRT-Y90 with Placebo | — | — | — | — | — | 1 | |
| Sacituzumab Tirumotecan | — | — | — | — | — | 1 | |
| Oral Dacomitinib | — | — | — | — | — | 1 | |
| Adjuvant Atezolizumab-Bevacizumab Therapy | — | — | — | — | — | 1 | |
| Oral Lenvatinib + Intravenous (IV) Pembrolizumab + Oral Letrozole | — | — | — | — | — | 1 | |
| Low Dose OXIRI | — | — | — | — | — | 1 | |
| CCRT with Maintenance Tislelizumab and Metronomic Capecitabine | — | — | — | — | — | 1 | |
| Dacomitinib | — | — | — | — | — | 1 | |
| Oral S-1 + Oral Osimertinib | — | — | — | — | — | 1 | |
| Neoantigen Dendritic Cell Vaccine | — | — | — | — | — | 1 | |
| Intramuscular ACM-CpG Monotherapy | — | — | — | — | — | 1 |
Next readouts
- 2025-10-24
- 2026-03-31
- 2026-07-25
- 2026-12
- 2026-12
- 2026-12-31
- 2027-02-28
- 2027-03
- 2027-04
- 2027-04-05
Top conditions
- Hepatocellular Carcinoma9
- Breast Cancer9
- Head and Neck Cancer6
- Colorectal Cancer6
- Non-Small Cell Lung Cancer5
- Nasopharyngeal Carcinoma5
- Cancer4
- Non-small Cell Lung Cancer4
Frequently asked questions about National Cancer Centre, Singapore
- How many clinical trials does National Cancer Centre, Singapore have on ClinicalTrials.gov?
- National Cancer Centre, Singapore is listed as the lead sponsor on 113 clinical trials in ClinicalTrials.gov, 34 of which are currently active (recruiting, enrolling, or ongoing).
- How many of National Cancer Centre, Singapore's trials are in Phase 3?
- 7 of National Cancer Centre, Singapore's trials are in Phase 3, spread across 15 active drug programs.
- What therapeutic areas does National Cancer Centre, Singapore focus on?
- National Cancer Centre, Singapore's most-studied conditions on ClinicalTrials.gov are Hepatocellular Carcinoma, Breast Cancer, Head and Neck Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer.
- When are National Cancer Centre, Singapore's next clinical trial readouts?
- National Cancer Centre, Singapore has 10 upcoming primary-completion readouts tracked here; the soonest is “A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC”, expected around 2025-10-24.